Meeting Banner
Abstract #2569

Evaluating the Role of PIRADS V2  and TRUSgBX for Improving Detection of Clinically Significant Prostate Cancer at Radical Prostatectomy

Alireza Ziaei1, Francesco Alessandrino1,2, Mark Vangel3, Tina Kapur1, Clare Mary Tempany1, and Fiona Mary Fennessy1,2

1Dept. of Radiology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States, 2Dept. of Imaging, Dana–Farber Cancer Institute, Boston, MA, United States, 3Dept. of Radiology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, United States

The aim of this retrospective study was to determine a role for PIRADS V2 in conjunction with TRUSgBX to predict the presence of clinically significant prostate cancer (csPCa) in treatment naïve men with pathology-proven prostate cancer who underwent TRUSgBX, followed by 3T mp-MRI prostate, and subsequently underwent RP. Our findings suggest that adding PIRADS V2 assessment to TRUSgBX improves the prediction of final pathology for presence of indolent disease and csPCa, and may help alleviate the rate of upgrading at RP.

This abstract and the presentation materials are available to members only; a login is required.

Join Here